Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in Refractory Metastatic or Unresectable Squamous Cell Carcinoma of the Anus/Rectum
NCT07511023Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2026
- Primary completion
- Mar 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in anal squamous cell carcinoma (SCCA), squamous cell carcinoma of the rectum (RSCC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
anal squamous cell carcinoma (SCCA)squamous cell carcinoma of the rectum (RSCC)
Beyond the preview
Go deeper on NCT07511023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511023.